ANRO.US Alto Neuroscience, Inc.

Healthcare Pharmaceuticals USA Stocks
29.54 USD
Close of Nov 14, 2026
12.51 37.48
Market cap
USD 1.18B
P/E
-
P/B
4.14x
ROE
-32.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 4 quarters up to Sep 2026.

Is ANRO.US undervalued?

Graham number

The Graham number of Alto Neuroscience, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Alto Neuroscience, Inc. fundamental analysis

No fundamental analysis for Alto Neuroscience, Inc. yet.

Alto Neuroscience, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Alto Neuroscience, Inc.

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a no…

Full company profile